Beroukhim Lab
@rameenberoukhim.bsky.social
We study cancer evolution, alterations in chromosome structure, brain tumors, cancer genomics
This was a fun project with John Rhee and Charlotta Lindvall on using LLMs to scour medical records. It has been wonderful to work with them!
secure-web.cisco.com/1QgAtJ9SFoCj...
secure-web.cisco.com/1QgAtJ9SFoCj...
Scalable Tracking of Symptoms in the Electronic Health Record using Large Language Models in Patients with Central Nervous System Cancers Undergoing Therapy
AbstractBackground. Advances in large language models (LLMs) provide a means for scalable tracking of patient symptoms in clinical trials and post-marking
secure-web.cisco.com
September 18, 2025 at 5:30 PM
This was a fun project with John Rhee and Charlotta Lindvall on using LLMs to scour medical records. It has been wonderful to work with them!
secure-web.cisco.com/1QgAtJ9SFoCj...
secure-web.cisco.com/1QgAtJ9SFoCj...
Reposted by Beroukhim Lab
Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better
These children need MORE funding and MORE trials, not less.
They deserve better
August 19, 2025 at 10:41 PM
Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better
These children need MORE funding and MORE trials, not less.
They deserve better
Reposted by Beroukhim Lab
📣 Online now! Our study shows how recurrent focal deletions constitute a mechanism by which cancer cells can dampen toxicity due to gene amplification.
www.cell.com/cell-genomic...
🧵👇:
www.cell.com/cell-genomic...
🧵👇:
Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification
Wala et al. identify recurrent focal BRD4 deletions in tumors harboring larger amplifications,
suggesting that these deletions may serve to limit toxic BRD4 overexpression. A CRISPR-Cas9
cell line mod...
www.cell.com
March 19, 2025 at 3:43 PM
📣 Online now! Our study shows how recurrent focal deletions constitute a mechanism by which cancer cells can dampen toxicity due to gene amplification.
www.cell.com/cell-genomic...
🧵👇:
www.cell.com/cell-genomic...
🧵👇:
My postdoc received a perfect "10" on her MOSAIC K99/R00 application and is half a year in. She just got an email that the program is being terminated and, it seems, she won't be funded for future years.
April 2, 2025 at 6:26 PM
My postdoc received a perfect "10" on her MOSAIC K99/R00 application and is half a year in. She just got an email that the program is being terminated and, it seems, she won't be funded for future years.
Reposted by Beroukhim Lab
Supper happy to see the results of our longstanding collaboration in @naturecomms.bsky.social. We identify RBM14 as an ARGOS gene to modulate cGAS-STING signalling. Driven by @ms01.bsky.social and @vrendo.bsky.social with @bendavidlab.bsky.social and @rameenberoukhim.bsky.social. rdcu.be/d7Mky
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
Nature Communications - In cancer, the impact on cellular fitness of copy-number gains affecting collaterally-amplified genes remains poorly understood compared to oncogenes. Here, the authors...
rdcu.be
January 28, 2025 at 10:11 AM
Supper happy to see the results of our longstanding collaboration in @naturecomms.bsky.social. We identify RBM14 as an ARGOS gene to modulate cGAS-STING signalling. Driven by @ms01.bsky.social and @vrendo.bsky.social with @bendavidlab.bsky.social and @rameenberoukhim.bsky.social. rdcu.be/d7Mky
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma | Science Translational Medicine www.science.org/doi/abs/10.1...
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
In patients with glioblastoma, navtemadlin resistance is not mediated by TP53-inactivating mutations, and combination with TMZ may improve efficacy.
www.science.org
February 26, 2025 at 1:11 AM
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma | Science Translational Medicine www.science.org/doi/abs/10.1...
Reposted by Beroukhim Lab
Looking to see how #RiboSeq can improve your cancer research?
Check out how we've been developing new methods to study #medulloblastoma and other forms of #childhoodcancer.
Out in @naturecomms.bsky.social now. Thanks to Jim Clauwaert and Gerben Menschaert as well!
www.nature.com/articles/s41...
Check out how we've been developing new methods to study #medulloblastoma and other forms of #childhoodcancer.
Out in @naturecomms.bsky.social now. Thanks to Jim Clauwaert and Gerben Menschaert as well!
www.nature.com/articles/s41...
Deep learning to decode sites of RNA translation in normal and cancerous tissues - Nature Communications
RNA translation is a core cell process that is deregulated in cancer. Here, the authors show that a machine learning approach, RiboTIE, can reconstruct RNA translation in cancer and non-cancer cells. ...
www.nature.com
February 2, 2025 at 8:01 PM
Looking to see how #RiboSeq can improve your cancer research?
Check out how we've been developing new methods to study #medulloblastoma and other forms of #childhoodcancer.
Out in @naturecomms.bsky.social now. Thanks to Jim Clauwaert and Gerben Menschaert as well!
www.nature.com/articles/s41...
Check out how we've been developing new methods to study #medulloblastoma and other forms of #childhoodcancer.
Out in @naturecomms.bsky.social now. Thanks to Jim Clauwaert and Gerben Menschaert as well!
www.nature.com/articles/s41...